In a major development for the Swiss pharmaceutical sector, South Korean contract manufacturer Samsung Biologics has submitted a CHF1.5 billion cash offer to acquire Polypeptide, a key Swiss producer of active pharmaceutical ingredients.
LIVE·about 7 hours ago